Antiatherogenic property of triterpenoids-enriched extract from the aerial parts of Salvia miltiorrhiza

Phytotherapy Research

Volumn 22, Issue 8, 2008, Pages 1040-1045

  Zhang, Qin ^a,b   Chang, Zai ^b   Yang, Jie ^a   Wang, Qiang ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Atherosclerosis; CRP MCP 1; Salvia miltiorrhiza bunge; Triterpenoids

Indexed keywords

C REACTIVE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SALVIA MILTIORRHIZA EXTRACT; TRITERPENOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIATHEROGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AORTA ATHEROSCLEROSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG MEGADOSE; DRUG SYNTHESIS; FEMALE; HYPOCHOLESTEROLEMIA; INFLAMMATION; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; XANTHOMATOSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTILIPEMIC AGENTS; AORTA; ATHEROSCLEROSIS; BEHAVIOR, ANIMAL; C-REACTIVE PROTEIN; CHEMOKINE CCL2; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUGS, CHINESE HERBAL; FEMALE; LIPIDS; LONGEVITY; MALE; MICE; MICE, KNOCKOUT; PLANT COMPONENTS, AERIAL; SALVIA; SKIN DISEASES; TRITERPENES; XANTHOMATOSIS;

MUS; SALVIA MILTIORRHIZA;

EID: 50149083047     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2426     Document Type: Article

References (23)

1. Brown MS, Goldstein JL. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34-47.
2. Chang MK, Binder CJ, Torzewski M, Witztum JL. 2002. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 99: 13043-13048.
3. Cyrus T, Yao Y, Tung LX, Pratico D. 2006. Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin. Atherosclerosis 184: 8-14.
4. De Felice A, Bader A, Leone A et al. 2006. New polyhydroxylated triterpenes and anti-inflammatory activity of Salvia hierosolymitana. Planta Med 72: 643-649.
5. Gotto AM, Grundy SM. 1999. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial. Data Issues from the interdisciplinary council on reducing the risk for coronary heart disease, ninth council meeting. Circulation 99: E1-E7.
6. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. 1993. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92: 883-893.
7. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. 1994. Massive xanthomatosis and atherosclerosis in cholesterolfed low density lipoprotein receptor-negative mice. J Clin Invest 93: 1885-1893.
8. Lee WS, Im KR, Park YD, Sung ND, Jeong TS. 2006. Human ACAT-1 and ACAT-2 inhibitory activities of pentacyclic triterpenes from the leaves of Lycopus lucidus TUBCZ. Biol Pharm Bull 29: 382-384.
9. Libby P. 2002. Inflammation in atherosclerosis. Nature 420: 868-874.
10. Ma CM, Cai SQ, Cui JR et al. 2005. The cytotoxic activity of ursolic acid derivatives. Eur J Med Chem 40: 582-589.
11. Orchard GE, Wilson Jones E, Russell Jones R. 1994. Verruciform xanthoma: an immunocytochemical study. Br J Biomed Sci 51: 28-34.
12. Ovesna Z, Vachalkova A, Horvathova K, Tothova D. 2004. Pentacyclic triterpenoic acids: new chemoprotective compounds. Neoplasma 51: 327-333.
13. Pasceri V, Cheng JS, Willerson JT, Yeh ET. 2001. Modulation of C-reactive protein-mediated monocyte chemoat-tractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103: 2531-2534.
14. Pozo M, Castilla V, Gutierrez C, de Nicolas R, Egido J, Gonzalez-Cabrero J. 2006. Ursolic acid inhibits neointima formation in the rat carotid artery injury model. Atherosclerosis 184: 53-62.
15. Ross R. 1999. Atherosclerosis: an inflammatory disease. N Engl J Med 340: 115-126.
16. Safayhi H, Sailer ER. 1997. Anti-inflammatory actions of pentacyclic triterpenes. Planta Med 63: 487-493.
17. Setzer WN, Setzer MC. 2003. Plant-derived triterpenoids as potential antineoplastic agents. Mini Rev Med Chem 3: 540-556.
18. Tangirala RK, Pratico D, FitzGerald GA et al. 2001. Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem 276: 261-266.
19. Tangirala RK, Rubin EM, Palinski W. 1995. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 36: 2320-2328.
20. Topcu G. 2006. Bioactive triterpenoids from Salvia species. J Nat Prod 69: 482-487.
21. Wang X, Morris-Natschke SL, Lee KH. 2006. New developments in the chemistry and biology of the bioactive constituents of tanshen. Med Res Rev 27: 133-148.
22. Yla-Herttuala S, Lipton BA, Rosenfeld ME et al. 1991. Expression of monocyte chemoattractant protein 1 in macrophagerich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 88: 5252-5256.
23. Zhang Q, Chang Z, Wang Q. 2006. Ursane triterpenoids inhibit atherosclerosis and xanthoma in LDL receptor knockout mice. Cardiovasc Drugs Ther 20: 349-357.